Fate Therapeutics, Inc. (FATE)
| Market Cap | 2.13B |
| Revenue (ttm) | 68.26M |
| Net Income (ttm) | -253.72M |
| Shares Out | 97.00M |
| EPS (ttm) | -2.44 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 1,522,585 |
| Open | 22.14 |
| Previous Close | 22.47 |
| Day's Range | 21.34 - 22.56 |
| 52-Week Range | 17.10 - 66.56 |
| Beta | 1.67 |
| Analysts | Buy |
| Price Target | 76.04 (+246.1%) |
| Earnings Date | Nov 2, 2022 |
About FATE
Fate Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops programmed cellular immunotherapies for cancer and immune disorders worldwide. Its NK- and T-cell immuno-oncology programs under development include FT516 for the treatment of acute myeloid leukemia (AML) B-cell lymphoma, and advanced solid tumor; FT596 to treat B-cell lymphoma and chronic lymphocytic leukemia; FT538 to treat AML and multiple myeloma; FT576 to treat multiple myeloma; FT819 to treat hematologic malignancies and solid tumors; FT536 to treat solid tumors... [Read more...]
Financial Performance
In 2021, FATE's revenue was $55.85 million, an increase of 77.66% compared to the previous year's $31.43 million. Losses were -$212.15 million, 22.4% more than in 2020.
Financial StatementsAnalyst Forecast
According to 28 analysts, the average rating for FATE stock is "Buy." The 12-month stock price forecast is 76.04, which is an increase of 246.11% from the latest price.
News
Fate Therapeutics (FATE) Down 17% Since Last Earnings Report: Can It Rebound?
Fate Therapeutics (FATE) reported earnings 30 days ago. What's next for the stock?
Fate Therapeutics to Participate at Upcoming September Investor Conferences
SAN DIEGO, Sept. 02, 2022 (GLOBE NEWSWIRE) -- Fate Therapeutics, Inc. (the “Company” or “Fate Therapeutics”) (NASDAQ: FATE), a clinical-stage biopharmaceutical company dedicated to the development of pr...
The 5 Top Stocks Cathie Wood Is Buying Now
Cathie Wood's Ark Invest has performed well recently, with shares of her flagship exchange-traded fund (ETF), the ARK Innovation ETF (NYSEMKT: ARKK ), up more than 15% during the past month. The perform...
3 Cathie Wood Stocks for the Future
Unlike a lot of tech investors, Cathie Wood is super bullish on biotechnology. Here are three of her picks that these Motley Fool contributors love.
Cathie Wood Is Buying Up Red-Hot Fate Therapeutics (FATE) Stock
Source: ra2 studio/Shutterstock Shares of Fate Therapeutics (NASDAQ: FATE ) stock are up 3% following a massive purchase by two of Cathie Wood's exchange-traded funds (ETFs). Fate is a clinical stage bi...
ARK's Cathie Wood Dumps More Twitter Stock, Buys $20M in Fate Therapeutics Stock
Cathie Wood-led Ark Investment Management has bought 628,060 shares of clinical-stage biopharmaceutical company Fate Therapeutics Inc. (NASDAQ: FATE) through two of the firm's exchange-traded funds (ETF...
7 Small-Cap Stocks to Buy Before the Bull Market Returns
Small-cap stocks with lower market capitalizations ranging from $300 million to $2 billion have taken quite a hit since January. These stocks typically belong to smaller companies with massive long-term...
FATE's Q2 Loss Narrower Than Expected, Pipeline in Focus
FATE reports a narrower loss and higher collaboration revenues in the second quarter.
Fate Therapeutics (FATE) Reports Q2 Loss, Tops Revenue Estimates
Fate Therapeutics (FATE) delivered earnings and revenue surprises of 8.14% and 38.21%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?
Fate Therapeutics Reports Second Quarter 2022 Financial Results and Highlights Operational Progress
FT596+R Enrollment Ongoing in Multi-dose, Multi-cycle Cohorts for R/R BCL; Initiated Study Start-up for Investigation of FT596+R-CHOP in Newly-diagnosed Patients with Aggressive BCL
7 Cathie Wood Stocks Trading at a Discount Right Now
Cathie Wood stocks trading at a discount is our topic for today. The prominent fund manager and her team focus on disruptive innovation, considered by many to be a new paradigm in investing.
Fate Therapeutics to Webcast Conference Call Reporting Second Quarter 2022 Financial Results
SAN DIEGO, July 25, 2022 (GLOBE NEWSWIRE) -- Fate Therapeutics, Inc. (the “Company” or “Fate Therapeutics”) (NASDAQ: FATE), a clinical-stage biopharmaceutical company dedicated to the development of pro...
Despite Durability Questions, BMO Upgraded This Natural-Killer Cell Therapy Oncology Stock
BMO Capital Market upgraded Fate Therapeutics Inc (NASDAQ: FATE) to Outperform from Market Perform. The analyst believes Fate's iPSC platform is uniquely positioned in the cell therapy space.
Trial Results Set to Make or Break Small-Cap Pharma Stocks
One analyst is putting the odds at three to one that tests of a Karuna Therapeutics Inc. ( KRTX , Financial) schizophrenia drug will meet study objectives, paving the way to Food and Drug Administration...
Fate Therapeutics Appoints Brian T. Powl as Chief Commercial Officer
SAN DIEGO, June 30, 2022 (GLOBE NEWSWIRE) -- Fate Therapeutics, Inc. (NASDAQ: FATE), a clinical-stage biopharmaceutical company dedicated to the development of programmed cellular immunotherapies for ca...
Fate Therapeutics Announces Expansion of Solid Tumor Collaboration with ONO Pharmaceutical for Off-the-Shelf, iPSC-de...
ONO to Contribute Novel Binding Domains for a Second Solid Tumor Antigen to the Collaboration
Nkarta Stock a Bargain Compared to Fate Therapeutics
Investors who like Fate Therapeutics Inc. ( FATE , Financial) should love Nkarta Inc. ( NKTX , Financial).
Why Is Fate Therapeutics (FATE) Down 14.1% Since Last Earnings Report?
Fate Therapeutics (FATE) reported earnings 30 days ago. What's next for the stock?
Fate Therapeutics to Present at the 2022 Jefferies Global Healthcare Conference
SAN DIEGO, June 03, 2022 (GLOBE NEWSWIRE) -- Fate Therapeutics, Inc. (the “Company” or “Fate Therapeutics”) (NASDAQ: FATE), a clinical-stage biopharmaceutical company dedicated to the development of pro...
Fate Therapeutics to Present at Upcoming May Investor Conferences
SAN DIEGO, May 06, 2022 (GLOBE NEWSWIRE) -- Fate Therapeutics, Inc. (the “Company” or “Fate Therapeutics”) (NASDAQ: FATE), a clinical-stage biopharmaceutical company dedicated to the development of prog...
FATE's Loss Narrower Than Expected in Q1, Pipeline in Focus
FATE reports a narrower loss and higher collaboration revenues in the first quarter.
Fate Therapeutics (FATE) Reports Q1 Loss, Tops Revenue Estimates
Fate Therapeutics (FATE) delivered earnings and revenue surprises of 12.82% and 85.93%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?
Fate Therapeutics Reports First Quarter 2022 Financial Results and Highlights Operational Progress
FT596+R Enrollment Ongoing in Single- and Multi-dose, Multi-cycle Cohorts for R/R BCL